Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 18/20 | 0.80 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | MIF | P14174 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193491 | 0.99 | GLS (0.82) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL17655086 | 0.91 | GLS (0.98) | GLS | |
| SCHEMBL14987305 | 0.89 | GLS (1.00) | GLS | |
| SCHEMBL5345562 | 0.88 | GLS (0.67) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL15724893 | 0.87 | GLS (0.67) | GLS | |
| SCHEMBL17193287 | 0.87 | GLS (0.66) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL1011592 | 0.86 | POLB (0.68) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL17193290 | 0.86 | GLS (0.65) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL17193292 | 0.85 | GLS (0.64) | GLSLMNAMEN1ALDH1A1POLB | |
| SCHEMBL17193289 | 0.85 | GLS (0.64) | GLSLMNAMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | GLS 1/4885LMNA 4026/4885MEN1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.